DK2900230T3 - Forbindelser til behandling af adipositas og fremgangsmåder til anvendelse deraf - Google Patents

Forbindelser til behandling af adipositas og fremgangsmåder til anvendelse deraf Download PDF

Info

Publication number
DK2900230T3
DK2900230T3 DK13773562.7T DK13773562T DK2900230T3 DK 2900230 T3 DK2900230 T3 DK 2900230T3 DK 13773562 T DK13773562 T DK 13773562T DK 2900230 T3 DK2900230 T3 DK 2900230T3
Authority
DK
Denmark
Prior art keywords
celastrol
mice
obese
leptin
day
Prior art date
Application number
DK13773562.7T
Other languages
English (en)
Inventor
Umut Ozcan
Joseph Majzoub
Ralph Mazitschek
Isin Cakir
Serkan Cabi
Original Assignee
Childrens Medical Ct Corp
Massachusetts Gen Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49304418&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2900230(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Childrens Medical Ct Corp, Massachusetts Gen Hospital filed Critical Childrens Medical Ct Corp
Application granted granted Critical
Publication of DK2900230T3 publication Critical patent/DK2900230T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2264—Obesity-gene products, e.g. leptin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Claims (11)

1. Farmaceutisk formulering til anvendelse ved inducering af vægttab eller reduktion af kropsfedt eller en kombination deraf hos en præ-adipøs, adipøs eller sygeligt adipøs patient ved oral indgivelse af et vægttabsmiddel i en mængde mellem 0,005 mg og 10 mg pr. dag pr. kg kropsvægt; hvor formuleringen omfatter et vægttabsmiddel, som er en forbindelse defineret af formel I
Formel I; eller et farmaceutisk acceptabelt salt deraf.
2. Formulering til anvendelse ifølge krav 1, hvor forbindelsen i formel I indgives oralt til individet i en dosis på mellem 0,005 mg og 1,0 mg pr. kg kropsvægt pr. dag.
3. Formulering til anvendelse ifølge krav 1 eller 2, hvor forbindelsen med formel I indgives oralt til individet i en dosis på mellem 0,05 mg og 1,0 mg pr. kg kropsvægt pr. dag.
4. Formulering til anvendelse ifølge et hvilket som helst af kravene 1 til 3, hvor forbindelsen med formel I indgives oralt til individet i en dosis på mellem 0,05 mg og 0,1 mg pr. kg kropsvægt pr. dag.
5. Formulering til anvendelse ifølge et hvilket som helst af kravene 1 til 4, hvor formuleringen til anvendelse endvidere omfatter leptin.
6. Formulering til anvendelse ifølge et hvilket som helst af kravene 1 til 4, hvor den farmaceutiske formulering skal indgives i en virksom mængde til reduktion af kropsmasse med mindst 10 %, mere foretrukket med mindst 15 %, mest foretrukket med mindst 20 %.
7. Formulering til anvendelse ifølge et hvilket som helst af kravene 1 til 4, hvor den farmaceutiske formulering skal indgives i en virksom mængde til reduktion af kropsfedt med mindst 10 %, mere foretrukket med mindst 15 %, mest foretrukket med mindst 20 %.
8. Formulering til anvendelse ifølge et hvilket som helst af kravene 1 til 7, til anvendelse ved behandling af en patient med et kropsmasseindeks på mere end 40 kg/m2.
9. Formulering til anvendelse ifølge et hvilket som helst af kravene 1 til 8, til anvendelse ved behandling af en patient, der er sygeligt adipøs.
10. Formulering til anvendelse ifølge et hvilket som helst af kravene 1 til 4, til anvendelse ved behandling af en patient, der er leptin-resistent.
11. Formulering til anvendelse ifølge et hvilket som helst af kravene 1 til 4, til anvendelse ved behandling af en patient, som har et forhøjet niveau af leptin.
DK13773562.7T 2012-09-27 2013-09-26 Forbindelser til behandling af adipositas og fremgangsmåder til anvendelse deraf DK2900230T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261706153P 2012-09-27 2012-09-27
PCT/US2013/061911 WO2014052583A1 (en) 2012-09-27 2013-09-26 Compounds for the treatment of obesity and methods of use thereof

Publications (1)

Publication Number Publication Date
DK2900230T3 true DK2900230T3 (da) 2018-11-12

Family

ID=49304418

Family Applications (1)

Application Number Title Priority Date Filing Date
DK13773562.7T DK2900230T3 (da) 2012-09-27 2013-09-26 Forbindelser til behandling af adipositas og fremgangsmåder til anvendelse deraf

Country Status (21)

Country Link
US (5) US9968575B2 (da)
EP (3) EP3434268B1 (da)
JP (2) JP6480864B2 (da)
CN (3) CN111529535A (da)
AU (3) AU2013323528B2 (da)
BR (1) BR112015006848A2 (da)
CA (2) CA2886393C (da)
CY (1) CY1121166T1 (da)
DK (1) DK2900230T3 (da)
ES (1) ES2696626T3 (da)
HK (1) HK1213190A1 (da)
HR (1) HRP20181879T1 (da)
HU (1) HUE040496T2 (da)
LT (1) LT2900230T (da)
PL (1) PL2900230T3 (da)
PT (1) PT2900230T (da)
RS (1) RS58010B1 (da)
RU (2) RU2650646C2 (da)
SI (1) SI2900230T1 (da)
TR (1) TR201815668T4 (da)
WO (1) WO2014052583A1 (da)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2900230T (lt) 2012-09-27 2019-01-10 The Children`S Medical Center Corporation Junginiai, skirti nutukimo gydymui ir jų panaudojimo būdai
CA3044998A1 (en) * 2014-03-26 2015-10-01 The Children's Medical Center Corporation Celastrol and derivatives for the treatment of obesity
WO2015153933A1 (en) * 2014-04-03 2015-10-08 The Children's Medical Center Corporation Hsp90 inhibitors for the treatment of obesity and methods of use thereof
CN105985401B (zh) * 2015-02-16 2020-10-09 上海华拓医药科技发展有限公司 一种雷公藤红素衍生物、其制备方法及用途
EP3364956A4 (en) * 2015-10-23 2019-05-01 ERX Pharmaceuticals, Inc. CELASTROL ANALOGUES
CN106905404B (zh) * 2017-01-13 2019-08-27 广东工业大学 熊果酸衍生物及其制备方法和应用
KR102470686B1 (ko) * 2022-06-07 2022-11-23 서울대학교산학협력단 디메틸제일아스테럴을 포함하는 대사성 질환 예방 또는 치료용 약학 조성물

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU531759B2 (en) 1978-04-17 1983-09-08 Ici Ltd. Electrostatic spraying
GB8504253D0 (en) 1985-02-19 1985-03-20 Ici Plc Electrostatic spraying apparatus
US4938763B1 (en) 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
MY107937A (en) 1990-02-13 1996-06-29 Takeda Chemical Industries Ltd Prolonged release microcapsules.
US6001968A (en) 1994-08-17 1999-12-14 The Rockefeller University OB polypeptides, modified forms and compositions
US6350730B1 (en) 1994-08-17 2002-02-26 The Rockefeller University OB polypeptides and modified forms as modulators of body weight
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
US6429290B1 (en) 1994-08-17 2002-08-06 The Rockefeller University OB polypeptides, modified forms and derivatives
US5827734A (en) 1995-01-20 1998-10-27 University Of Washington Materials and methods for determining ob protein in a biological sample
US5532336A (en) 1995-01-31 1996-07-02 Eli Lilly And Company Anti-obesity proteins
US5552524A (en) 1995-01-31 1996-09-03 Eli Lilly And Company Anti-obesity proteins
US5521283A (en) 1995-01-31 1996-05-28 Eli Lilly And Company Anti-obesity proteins
US5552523A (en) 1995-01-31 1996-09-03 Eli Lilly And Company Anti-obesity proteins
US5552522A (en) 1995-01-31 1996-09-03 Eli Lilly And Company Anti-obesity proteins
WO1996040912A1 (en) 1995-06-07 1996-12-19 Amgen Inc. Ob protein compositions and method
IL122718A0 (en) 1995-06-30 1998-08-16 Lilly Co Eli Methods for treating diabetes
DE69631605T2 (de) 1995-08-17 2005-01-05 Amgen Inc., Thousand Oaks Verfahren zur verringerung und zur erhaltung von verringerten blutspiegeln von lipiden mittels zubereitungen von ob-proteinen
US5650167A (en) * 1995-11-16 1997-07-22 Dawa Incorporated Method and composition for treating hepatitis B
PT866720E (pt) 1995-11-22 2004-06-30 Amgen Inc Proteina ob para aumentar a massa do tecido mole
US20030040467A1 (en) 1998-06-15 2003-02-27 Mary Ann Pelleymounter Ig/ob fusions and uses thereof.
US6936439B2 (en) 1995-11-22 2005-08-30 Amgen Inc. OB fusion protein compositions and methods
WO1997038014A1 (en) 1996-04-04 1997-10-16 Amgen Inc. Fibulin pharmaceutical compositions and related methods
EP1001768A1 (en) 1996-08-30 2000-05-24 Amgen Inc. Methods of increasing sensitivity of an individual to ob protein by upregulating ob protein receptor
AU735178B2 (en) 1996-09-20 2001-07-05 Hoechst Aktiengesellschaft Use of leptin antagonists for treating insulin resistance in type II diabetes
ATE272394T1 (de) 1996-10-31 2004-08-15 Takeda Chemical Industries Ltd Zubereitung mit verzögerter freisetzung
US5880116A (en) * 1996-12-13 1999-03-09 Neurocal International Use of celastrol to treat alzheimer's disease
NZ514145A (en) 1996-12-20 2003-08-29 Amgen Inc OB fusion protein compositions and methods
JP4086908B2 (ja) 1997-04-17 2008-05-14 アムジエン・インコーポレーテツド 安定かつ活性なヒトＯＢタンパク質と抗体Ｆｃ鎖とのコンジュゲートを含む組成物および方法
KR20010013414A (ko) 1997-06-06 2001-02-26 피터 기딩스 당뇨병의 치료를 위한 렙틴 길항제의 용도
US7052678B2 (en) 1997-09-15 2006-05-30 Massachusetts Institute Of Technology Particles for inhalation having sustained release properties
US6541033B1 (en) 1998-06-30 2003-04-01 Amgen Inc. Thermosensitive biodegradable hydrogels for sustained delivery of leptin
EP1107793B1 (en) 1998-08-10 2004-10-27 Amgen Inc. Dextran-leptin conjugates, pharmaceutical compositions and related methods
JP2002526780A (ja) 1998-10-02 2002-08-20 アムジエン・インコーポレーテツド レプチン処置に対する素因の決定方法
US6420339B1 (en) 1998-10-14 2002-07-16 Amgen Inc. Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility
JP4841037B2 (ja) 1999-02-12 2011-12-21 アムジエン・インコーポレーテツド グリコシル化レプチン組成物および関連する方法
DK2219031T3 (da) 2001-10-22 2013-06-17 Amgen Inc Anvendelse af leptin til behandling af human lipoatrofi og fremgangsmåde til bestemmelse af prædisposition for behandlinngen
NZ539642A (en) * 2002-10-21 2007-01-26 Metaproteomics Llc Compositions containing extracts from hops in combination with a second component for treating inflammatory response
WO2004039832A2 (en) 2002-10-31 2004-05-13 Albany Medical College Leptin-related peptides
RU2346688C2 (ru) * 2002-12-06 2009-02-20 Фиброген, Инк. Регулирование содержания жира
US7776484B2 (en) 2004-01-16 2010-08-17 Mitsubishi Materials Corporation Separator for fuel cell, method for producing separator, and solid oxide fuel cell
US20060253100A1 (en) * 2004-10-22 2006-11-09 Medtronic, Inc. Systems and Methods to Treat Pain Locally
WO2007043302A1 (ja) 2005-09-30 2007-04-19 Morinaga Milk Industry Co., Ltd. インスリン抵抗性改善剤
US8088759B2 (en) 2005-11-01 2012-01-03 The Regents Of The University Of Michigan 1,4-benzodiazepine-2,5-diones with therapeutic properties
AU2007230991A1 (en) 2006-03-22 2007-10-04 Syndexa Pharmaceuticals Corporation Compounds and methods for treatment of disorders associated with ER stress
US20110263693A1 (en) * 2006-03-31 2011-10-27 Dana-Farber Cancer Institute, Inc. Celastrol, gedunin, and derivatives thereof as hsp90 inhibitors
US20080044390A1 (en) 2006-08-11 2008-02-21 Xiaowei Jin Methods and compositions for the treatment of neurodegenerative disorders
WO2008020622A1 (fr) * 2006-08-17 2008-02-21 Kyorin Pharmaceutical Co., Ltd. NOUVEAU COMPOSÉ DE THIÉNO[2,3-d]PYRIMIDINE
CN101686951A (zh) * 2006-11-13 2010-03-31 纽约市哥伦比亚大学托管会 治疗糖尿病的选择性蛋白酶体抑制物
CN101279995A (zh) * 2007-04-03 2008-10-08 烟台靶点药物研究有限公司 一种雷公藤红素盐及其制备方法与用途
US7776894B2 (en) 2007-08-17 2010-08-17 Burnham Institute For Medical Research Compositions and methods for inhibiting growth and metastasis of melanoma
AU2007360979B2 (en) * 2007-11-14 2014-04-10 Amylin Pharmaceuticals, Llc Methods for treating obesity and obesity related diseases and disorders
CN101434635B (zh) * 2007-11-16 2012-05-16 上海华拓医药科技发展股份有限公司 一类具抗肿瘤活性的水溶性酚性三萜化合物及其制备方法
WO2009067245A2 (en) * 2007-11-20 2009-05-28 University Of Florida Research Foundation, Inc. Compositions and methods for tissue repair
AU2009332930A1 (en) 2008-02-01 2009-08-13 The Scripps Research Institute Methods for treating a condition characterized by dysfunction in protein homeostasis
CN101352444A (zh) * 2008-09-11 2009-01-28 中国科学院广州生物医药与健康研究院 雷公藤红素在制药中的新应用
WO2010119674A1 (ja) * 2009-04-17 2010-10-21 国立大学法人広島大学 レプチン抵抗性を改善および／または予防するための薬学的組成物、並びにその使用
CN101704874A (zh) * 2009-11-26 2010-05-12 中国药科大学 五环三萜及其衍生物的二甲双胍盐、其制备方法及医药用途
ME03713B (me) 2010-04-12 2021-01-20 Reata Pharmaceuticals Inc Bardoksolon meтil za lečenje gojaznosтi
CN102309494A (zh) * 2010-07-01 2012-01-11 嘉兴学院 扁蒴藤素作为炎性细胞因子抑制剂的医药用途
JP2013536203A (ja) 2010-08-23 2013-09-19 スーチョウ・ニューファーマ・カンパニー・リミテッド 特定の化学成分、組成物および方法
EP2617726A4 (en) * 2010-09-17 2014-05-14 Takeda Pharmaceutical DIABETES THERAPEUTIC
KR101180387B1 (ko) 2011-11-21 2012-09-10 동국대학교 산학협력단 엣지 추출을 위한 이미지 센서 및 이를 이용한 엣지 이미지 생성 방법.
AU2013266086B2 (en) 2012-05-25 2018-03-01 Berg Llc Methods of treating a metabolic syndrome by modulating heat shock protein (HSP) 90-beta
LT2900230T (lt) * 2012-09-27 2019-01-10 The Children`S Medical Center Corporation Junginiai, skirti nutukimo gydymui ir jų panaudojimo būdai
CN103524592B (zh) 2013-09-27 2015-08-05 安徽医科大学 一种雷公藤红素衍生物、该衍生物的生物盐及其制备方法与用途
US9601471B2 (en) 2015-04-23 2017-03-21 Apple Inc. Three layer stack structure

Also Published As

Publication number Publication date
US20210275482A1 (en) 2021-09-09
EP2900230A1 (en) 2015-08-05
CN104822374A (zh) 2015-08-05
RU2650646C2 (ru) 2018-04-16
AU2018256619A1 (en) 2018-11-22
CA3030272A1 (en) 2014-04-03
LT2900230T (lt) 2019-01-10
RU2018112067A (ru) 2019-03-07
HUE040496T2 (hu) 2019-03-28
PT2900230T (pt) 2018-11-26
US20210008019A1 (en) 2021-01-14
JP6480864B2 (ja) 2019-03-13
BR112015006848A2 (pt) 2018-05-22
AU2016247206A1 (en) 2016-11-10
CN111529535A (zh) 2020-08-14
TR201815668T4 (tr) 2018-11-21
AU2018256619B2 (en) 2020-07-23
AU2013323528A1 (en) 2015-04-09
SI2900230T1 (sl) 2019-01-31
JP2015531376A (ja) 2015-11-02
US10653654B2 (en) 2020-05-19
EP2900230B1 (en) 2018-08-15
US11045439B2 (en) 2021-06-29
JP6743211B2 (ja) 2020-08-19
CA2886393A1 (en) 2014-04-03
EP3434268B1 (en) 2022-04-20
HK1213190A1 (zh) 2016-06-30
US20150250753A1 (en) 2015-09-10
US9925161B2 (en) 2018-03-27
AU2016247206B2 (en) 2018-08-02
CN111529534A (zh) 2020-08-14
CA3030272C (en) 2021-09-28
RU2768868C2 (ru) 2022-03-25
JP2019070052A (ja) 2019-05-09
AU2013323528B2 (en) 2016-11-10
RS58010B1 (sr) 2019-02-28
CY1121166T1 (el) 2020-05-29
RU2018112067A3 (da) 2021-06-24
ES2696626T3 (es) 2019-01-17
EP4082541A1 (en) 2022-11-02
EP3434268A1 (en) 2019-01-30
US9968575B2 (en) 2018-05-15
WO2014052583A1 (en) 2014-04-03
HRP20181879T1 (hr) 2019-02-08
PL2900230T3 (pl) 2019-02-28
RU2015115696A (ru) 2016-11-20
US20180185314A1 (en) 2018-07-05
US20170304245A1 (en) 2017-10-26
CA2886393C (en) 2019-02-26

Similar Documents

Publication Publication Date Title
DK2900230T3 (da) Forbindelser til behandling af adipositas og fremgangsmåder til anvendelse deraf
US10485774B2 (en) Enterically coated cysteamine, cystamine and derivatives thereof
EP3122347B1 (en) Celastrol derivatives for the treatment of obesity
WO2012142413A2 (en) Nitrite compositions and uses thereof
DK3074033T3 (da) Forbindelser til behandling af adipositas og fremgangsmåder til anvendelse deraf
WO2003015807A1 (en) Side effct-relieving agents and/or hypoglycemic effect enhancers for thiazolidine derivatives
EP3658130A1 (en) Modified-release bucillamine compositions, kits, and methods for treating cystinuria, arthritis, gout, and related disorders